K 8
Alternative Names: Inflammasome inhibitor-Inflammasome Therapeutics; K-8; Kamuvudine-8; SOM-401Latest Information Update: 22 Jul 2026
At a glance
- Originator Inflammasome Therapeutics
- Class Eye disorder therapies
- Mechanism of Action NLRC4 protein inhibitors; NLRP3 protein inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dry macular degeneration
- No development reported Diabetic macular oedema
Most Recent Events
- 17 Jul 2026 Updated efficacy and adverse events data from a phase I/II trial in Dry macular degeneration released by Inflammasome Therapeutics
- 17 Jul 2026 Inflammasome Therapeutics plans a global phase III pivotal trial in Dry macular degeneration (Intravitreous, Controlled-release, Implant)
- 15 May 2026 University of Kentucky completes a phase I/II trial in Dry macular degeneration in USA (Intravitreous) (NCT06164587)